ERAP1 as an emerging therapeutic target for medulloblastoma

Francesca Bufalieri; Doriana Fruci; Lucia Di Marcotullio

doi:10.1016/j.trecan.2021.09.005

ERAP1 as an emerging therapeutic target for medulloblastoma

Trends Cancer. 2022 Jan;8(1):4-8. doi: 10.1016/j.trecan.2021.09.005. Epub 2021 Oct 20.

Authors

Francesca Bufalieri¹, Doriana Fruci², Lucia Di Marcotullio³

Affiliations

¹ Department of Molecular Medicine, University La Sapienza, 00161 Rome, Italy.
² Paediatric Haematology/Oncology Department, Ospedale Pediatrico Bambino Gesù, IRCCS, 00146 Rome, Italy.
³ Department of Molecular Medicine, University La Sapienza, 00161 Rome, Italy; Istituto Pasteur-Fondazione Cenci Bolognetti, University La Sapienza, 00161 Rome, Italy. Electronic address: lucia.dimarcotullio@uniroma1.it.

PMID: 34686465
DOI: 10.1016/j.trecan.2021.09.005

Abstract

Endoplasmic reticulum aminopeptidase 1 (ERAP1) is a multifunctional enzyme that shapes the peptide repertoire presented by major histocompatibility complex class I (MHC-I) molecules, thereby affecting tumor immunogenicity. ERAP1 is altered in many tumors, including medulloblastoma (MB). We review the role of ERAP1 in MB development and the possibility of targeting this enzyme for MB treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Aminopeptidases / chemistry
Aminopeptidases / genetics
Cerebellar Neoplasms* / drug therapy
Cerebellar Neoplasms* / genetics
Histocompatibility Antigens Class I / genetics
Humans
Medulloblastoma* / drug therapy
Medulloblastoma* / genetics
Minor Histocompatibility Antigens / genetics

Substances

Histocompatibility Antigens Class I
Minor Histocompatibility Antigens
Aminopeptidases
ERAP1 protein, human